SCHEMBL5882473

SCHEMBL5882473

COC(=O)c1ccc2[nH]c(C)c(Cc3cccc(-c4ccccc4)c3)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 1/20 0.55
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 4/20 0.49
HSD17B10 Q99714 3/20 0.49
HPGD P15428 2/20 0.49
ALOX15 P16050 1/20 0.49
CASP1 P29466 1/20 0.49
CYP2C9 P11712 1/20 0.48
ATM Q13315 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALOX12 P18054 1/20 0.48
MAPK1 P28482 1/20 0.48
DHFR P00374 2/20 0.46
KIF11 P52732 1/20 0.45
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45
TUBA3C P0DPH7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5882112 0.91 PTPN5 (0.64) PTPN5MEN1KMT2AKDM4EALDH1A1
SCHEMBL5881928 0.83 MEN1 (0.50) PTPN5MEN1KMT2AKDM4EALDH1A1
SCHEMBL5882131 0.82 PTPN5 (0.64) PTPN5MEN1KMT2AKDM4EALDH1A1
SCHEMBL5881911 0.82 PTPN5 (0.60) PTPN5MEN1KMT2AKDM4EALDH1A1
SCHEMBL5881908 0.82 PTPN5 (0.60) PTPN5MEN1KMT2AKDM4EALDH1A1
SCHEMBL5127305 0.80 PTPN5 (0.58) PTPN5MEN1KMT2AKDM4EALDH1A1
SCHEMBL5132934 0.80 PTPN5 (0.63) PTPN5MEN1KMT2AKDM4EALDH1A1
SCHEMBL5131182 0.80 PTPN5 (0.63) PTPN5MEN1KMT2AKDM4EALDH1A1
SCHEMBL5881714 0.79 PTPN5 (0.72) PTPN5MEN1KMT2AKDM4EALDH1A1
SCHEMBL5882184 0.78 PDE3B (0.56) PTPN5MEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT PTPN5 2703/4885MEN1 852/4885KMT2A 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.